John Lechleiter, Eli Lilly CEO, and David Ricks, incoming Eli Lilly CEO, dicusses the need to make changes around the Affordable Care Act.
John Lechleiter, Eli Lilly CEO, and David Ricks, incoming Eli Lilly CEO talk about Eli Lilly's succession plan as the company launches a new chapter in its history.
John Lechleiter, Eli Lily CEO, breaks down the company's quarterly results which reported EPS of $0.86 Adj on revenues of $5.40 billion. Also Lechleiter provides an update on new drug approvals and weighs in on drug pricing.
CNBC's Meg Tirrell reports on the health of the biotech sector and what could spur a turnaround in the second half of the year.